Psychedelic Business Spotlight – March 18
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies.
Greg Gilman is Psychedelic Spotlight's lead content editor, as well as a contributor. His previous work has appeared in dozens of publications, including USA Today, Yahoo! News, TheWrap, MovieMaker Magazine and SyFy Wire. When he's not writing, he's the lead singer for LA-based Americana rock band Greg in Good Company. Given his experience as an artist, he's particularly interested in the intersection of psychedelics and entertainment.
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies.
The company was pursuing several psychedelic business strategies, including synthesizing ibogaine for researchers.
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
This week in psychedelic business news: Field Trip partners with Cerebral; Benzinga forms Psychedelic Advisory Council; Incannex pursues virtual reality psychedelic therapy.
Spoiler alert: It’s not because they’re depressed.
This week in psychedelic business news: Core One cheapens psilocybin production; Field Trip eyes Oregon; Small Pharma advances DMT.
Another study concludes with results challenging the increasingly popular narrative that microdosing psychedelics improves mood and cognitive function.
With no strong resistance manifesting to oppose the psychedelic renaissance, it appears these drugs have re-emerged from underground for a permanent place in our culture.
This week in psychedelic business news: Nova Mentis makes progress on autism; atai donates to MAPS; Cathie Wood eyes more psychedelic stocks.
Biotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.